In a significant advancement of its strategic growth initiatives, Synexa Life Sciences has acquired Alderley Analytical Ltd. This acquisition is a crucial element in Synexa’s ongoing ‘buy and build’ strategy, aimed at expanding and enhancing its capabilities in the biomarker and bioanalysis sectors. Known for its expertise in DNA, RNA, protein, cell, and tissue analysis, Synexa has positioned this merger as a pivotal milestone in its goal to support drug development through all phases of research and clinical trials. The addition of Alderley Analytical, with its specialized skills in mass spectrometry and ligand binding assays, will substantially broaden Synexa’s service portfolio, ultimately fostering more comprehensive and high-quality bioanalytical service offerings.
Alderley Analytical recently made headlines by relocating to a state-of-the-art GLP/GCP-accredited laboratory near Manchester, UK. This move is in alignment with its own ambitions to provide an extensive range of bioanalytical services tailored to the needs of preclinical and clinical drug development. The synergy between Synexa and Alderley Analytical is expected to yield significant benefits, not just in expanded geographical reach but also in service enhancements. Synexa’s CEO, Emile Lens, highlighted the strategic fit and the growth potential that this acquisition brings. Emphasizing both Alderley’s complementary capabilities and its geographic positioning, Lens expressed confidence that this merger would result in improved support for innovative therapies in the pharmaceutical industry.
Strategic Fit and Growth Potential
Synexa Life Sciences has taken a major step in its growth strategy by acquiring Alderley Analytical Ltd. This acquisition is a key part of Synexa’s ‘buy and build’ approach, designed to expand its capabilities in biomarker and bioanalysis. Synexa, known for its expertise in DNA, RNA, protein, cell, and tissue analysis, views this merger as a critical milestone in supporting drug development through all research and clinical trial phases. Adding Alderley Analytical’s skills in mass spectrometry and ligand binding assays significantly broadens Synexa’s services, aiming for more comprehensive and high-quality bioanalytical offerings.
Recently, Alderley Analytical relocated to a state-of-the-art GLP/GCP-accredited lab near Manchester, UK, aligning with its aim to offer a wide range of bioanalytical services for preclinical and clinical drug development. The synergy between Synexa and Alderley Analytical promises to bring substantial benefits, enhancing both geographical reach and service quality. Synexa’s CEO, Emile Lens, praised the strategic fit and growth potential, noting that Alderley’s complementary strengths and geographic location will enhance support for innovative therapies in the pharmaceutical industry.
